Lifecore Biomedical, Inc.
NASDAQ:LFCRDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $242.60M
- Beta
- 1.07
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$0.91
Volume 0.15M
Average 0.29M
LFCR Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Lifecore Biomedical, Inc.NASDAQ: LFCR
Selling, General & Admin · Q3 FY2026 · quarter ended Mar 2026
Selling, general & admin of $7.92M in Q3 FY2026
Q3 FY2026 selling, general & admin was $7.92M. Trailing-twelve-month selling, general & admin was $33.33M. Over 3 fiscal years it compounded at +8.3% a year.
Context
- Selling, general & admin amounted to 34.2% of revenue in FY2025, up 2.6 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of $24.35M (-44.7%) for the fiscal year ending May 2026, a slowdown from the +8.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $7.92M+5.0% QoQ
- Last fiscal yearMay 2025
- $44.05M+8.9% YoY
- LTMMar 2026
- $33.33M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +8.9% | -44.7% | -53.6 pp |
| 3-year CAGR | +8.3% | -1.4% | -9.7 pp |
| 5-year CAGR | +6.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 44.05M USD
- Year-over-year change
- +8.9%
- 4-year CAGR
- +12.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-05-25 | 44.05M | +8.9% |
| FY2024 | 2024-05-26 | 40.46M | +3.8% |
| FY2023 | 2023-05-28 | 38.97M | +12.4% |
| FY2022 | 2022-05-29 | 34.66M | +25.0% |
| FY2021 | 2021-05-31 | 27.72M | — |
Selling, General & Admin vs competitors
How LFCR compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Selling, general & admin amounts to 24.7% of revenue for LFCR, versus a peer median of 110.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$166.84M CAD | +0.2% | +0.7% | 53.7% | |
| LTM Mar 2026 | CA$134.01M CAD | +10.1% | -9.2% | 42.9% | |
| LTM Mar 2026 | $91.48M USD | -7.4% | -9.4% | 115.0% | |
| LTM Mar 2026 | $88.81M USD | +5.3% | +20.9% | 150.3% | |
| LTM Mar 2026 | $33.33M USD | — | +8.3% | 24.7% | |
| LTM Mar 2026 | $33.2M USD | +76.0% | +43.8% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $28.7M USD | +27.8% | +43.3% | 278.2% |
| LTM Mar 2026 | $27.13M USD | -1.6% | -10.3% | 64.9% | |
| LTM Mar 2026 | €14.33M EUR | +6.6% | -8.9% | 106.6% | |
| FY2025 | A$8.64M AUD | -2.4% | +6.2% | 171.4% | |
| Peer median (excluding LFCR) | — | +5.3% | +0.7% | 110.8% | |
Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 May 2021 | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 |
|---|---|---|---|---|---|
| Revenue | 100.87M | 111.27M | 103.27M | 128.26M | 128.87M |
| Cost of Revenue | 61.94M | 72.2M | 75.28M | 86.41M | 88.57M |
| Gross Profit | 38.94M | 39.07M | 27.99M | 41.85M | 40.3M |
| Gross Margin | 38.6% | 35.1% | 27.1% | 32.6% | 31.3% |
| Research & Development | 6.68M | 7.84M | 8.74M | 8.58M | 8.26M |
| Selling, General & Admin | 27.72M | 34.66M | 38.97M | 40.46M | 44.05M |
| Operating Expenses | 47.76M | 50.86M | 49.78M | 50.69M | 57.54M |
| Depreciation & Amortization | 19.87M | 18.06M | 13.18M | 8M | 8.03M |
| EBITDA | (987K) | 12.84M | (33.17M) | 35.6M | (8.81M) |
| EBITDA Margin | -1.0% | 11.5% | -32.1% | 27.8% | -6.8% |
| Operating Income | (8.82M) | (11.79M) | (21.8M) | (8.84M) | (17.25M) |
| Operating Margin | -8.7% | -10.6% | -21.1% | -6.9% | -13.4% |
| Interest Income | 48K | 81K | 68K | 0 | 0 |
| Interest Expense | 8.93M | 15.55M | 17.65M | 18.09M | 21.84M |
| Other Income / Expenses | (20.96M) | (8.9M) | (42.13M) | 18.36M | (21.43M) |
| Income Before Tax | (29.79M) | (20.69M) | (63.93M) | 9.51M | (38.67M) |
| Pre-Tax Margin | -29.5% | -18.6% | -61.9% | 7.4% | -30.0% |
| Income Tax Expense | (6.35M) | (5.21M) | 308K | 183K | 43K |
| Net Income | (32.29M) | (116.72M) | (99.56M) | 12.01M | (38.72M) |
| Net Margin | -32.0% | -104.9% | -96.4% | 9.4% | -30.0% |
| EPS (Basic) | (1.12) | (3.97) | (3.32) | 0.39 | (1.27) |
| EPS (Diluted) | (1.12) | (3.97) | (3.32) | 0.33 | (1.27) |
| Weighted Avg Shares | 29.29M | 29.47M | 29.96M | 30.47M | 34.82M |
| Weighted Avg Shares (Diluted) | 29.29M | 29.47M | 29.96M | 36.66M | 34.82M |
Lifecore Biomedical, Inc.
NASDAQ:LFCR
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.